Peps
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a label for a growth-hormone C-terminal fragment. The selected primary paper studied the related 177-191 fragment, so it is background evidence rather than confirmation of the exact 176-191 product.
Biological role or research focus
Fragment identity and fat-metabolism research.
The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.
Role reference: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Names you may encounter
GH fragment 176-191 · Human growth hormone fragment 176-191
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Growth-hormone C-terminal fragment label
- Research focus
- Fragment identity and fat-metabolism research
- Featured evidence
- Related fragment · Animal tissue study
- Source check
- October 4, 2026
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Biology & proposed mechanism
The experiment distinguished inhibition of fat synthesis from stimulation of fat breakdown. Those mechanisms should not be collapsed into a general weight-loss claim.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Research context & identity
This page separates fragments 176-191 and 177-191 from modified AOD-9604. Sequence and terminal modifications are necessary to identify the actual material.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Related fragment · Animal tissue study · 1993
GH fragment 177-191 in rat adipose tissue
What did this publication test, and what did it find?
- Population / model
- Rat adipose-tissue preparations.
- Study design
- Laboratory comparison of a synthetic GH 177-191 fragment using fat-synthesis and glycerol-release measurements.
- Main finding
- The fragment showed antilipogenic activity, but it did not significantly increase glycerol release as a lipolysis measure.
- Limits & context
- The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 1 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. ↗
Drug design, development and therapy · 2022 · Journal Article
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
This tissue experiment does not define systemic or human safety for any of these fragments.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Evidence boundaries
The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
3 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
HGH Fragment 176-191 Nedir? Yağ Yakımında Gerçekten İşe Yarar mı? ↗
Title match · Captions not indexed
Biohackingturkey
HGH Fragment 176-191: Gerçekler ve Riskler ↗
Title match · Captions not indexed
Biohackingturkey
HGH Fragment 176-191: Yağ Yakımının Peptidi! ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Are 176-191, 177-191, and AOD-9604 automatically interchangeable?
- What material, population, and route were actually studied?
- The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Are 176-191, 177-191, and AOD-9604 automatically interchangeable?
No. The exact sequence and modifications must be retained. This paper’s 177-191 result is labeled as related evidence.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.